
About Century Therapeutics
Century Therapeutics is a publicly listed company based in Philadelphia (United States) founded in 2018. Developer of adult stem cells to develop therapies for cancer. Century Therapeutics has raised $410 million across 4 funding rounds from investors including Fidelity Investments, Marshall Wace and FUJIFILM Cellular Dynamics. The company has 150 employees. Century Therapeutics has completed 3 acquisitions, including Clade TX, Empirica Therapeutics and empirica. Century Therapeutics offers products and services including iPSC-derived NK Cell Therapies and iPSC-derived T Cell Therapies. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is Century Therapeutics, Inc.
Company details
Century Therapeutics was founded in 2018 and is headquartered in Philadelphia, United States. Operations focus on the biotechnology sector, where adult stem cells are harnessed to create therapies targeting cancer. Novel allogeneic living drugs for oncology are being developed to address shortcomings in first-generation cell therapies. The companys efforts center on advancing these cellular treatments through research and development processes.
- Headquarters Philadelphia, United States
- Employees 150
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website centurytx.com
- Social LinkedIn X
- Legal Name Century Therapeutics, Inc.
- Annual Revenue$109.16 M (USD)1556.76as on Dec 31, 2025
- Net Profit-$9.58 M (USD)92.43as on Dec 31, 2025
- EBITDA-$1.94 M (USD)98.4as on Dec 31, 2025
- Total Equity Funding$410M (USD)
in 4 rounds
- Latest Funding Round$135M (USD), Post-IPO
Jan 2026
- InvestorsFidelity Investments
& 23 more
- Employee Count150
- Investments & AcquisitionsClade TX
& 2 more
Products & Services of Century Therapeutics
Century Therapeutics offers a comprehensive portfolio of products and services, including iPSC-derived NK Cell Therapies and iPSC-derived T Cell Therapies.
Engineered cells for cancer treatment through immune response.
Therapies targeting autoimmune diseases via cellular engineering.
Funding Insights of Century Therapeutics
Century Therapeutics has successfully raised a total of $410M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $135 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $410M
- Total Rounds 4
- Last Round Post-IPO β $135M
- First Round $250M
(Jul 2019)
- Investors Count 24
All 4 funding rounds of Century Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2026 | $135M | Post-IPO | β | TCG Crossover | |
| Apr 2024 | $60M | Post-IPO | β | β | |
| Mar 2021 | $160M | Series C | β | Casdin Capital | |
| Jul 2019 | $250M | Series C | β | Leaps by Bayer |
24 investors in total: 24 institutional.
Investors in Century Therapeutics
Century Therapeutics has secured backing from 24 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, Marshall Wace and FUJIFILM Cellular Dynamics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are focused on pharmaceutical, biotechnology, and medical sectors. | baincapitallifesciences.com | Boston, United States | ||
Investments in healthcare startups are managed by Octagon Capital Advisors. | octagoninvestments.com | New York, United States | ||
Investment firm focused on global life sciences and healthcare. | superstringcap.com | New York, United States | ||
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com | |||
Biotech startups are funded by this venture capital firm. | boxercap.com | San Diego, United States | ||
VC & PE firm focused on healthcare sector | venrockcp.com | Palo Alto, United States | ||
Private equity fund focused on the biotechnology sector | logoscapital.com | San Francisco, United States | ||
Long-short equity strategies are managed through specialized hedge funds. | 1997 | mwam.com | London, United Kingdom | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | versantventures.com |
Investor details for Century Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Century Therapeutics
33 people are tracked at Century Therapeutics (11 in leadership, 11 in board & advisors, 11 in team); the tracked headcount is 150.
| Name | Role | Group |
|---|---|---|
Danielle Menniti | Executive Director, Head Of Quality | Leadership |
Venkatesh Hariharan | Director | Leadership |
Johanna O'Bannon | Associate Director, QC Microbiology | Leadership |
Greg Russotti | Chief Technology And Manufacturing Officer | Leadership |
Michael Naso | VP, Cell Engineering | Leadership |
Bruno Marques | VP, Process & Product Development | Leadership |
Buddha Gurung | Director, Cell Engineering | Leadership |
Bruce Mittleman | Head Of Information Technology | Leadership |
Keith Wilson | Director, Manufacturing Science And Technology | Leadership |
Lindsay Mercado | Associate Director, Quality Esystems | Leadership |
Nayyereh Rajaei | Director, Drug Product Development And Delivery | Leadership |
Joe Jimenez | Chairman | Board & advisors |
Eli Casdin | Director | Board & advisors |
Hiromitsu Nakauchi | Scientific Advisor | Board & advisors |
Barbara Kee | Scientific Advisor | Board & advisors |
Kimberly Blackwell | Director | Board & advisors |
Alessandro Riva | Director | Board & advisors |
Ellen Rothenberg | Scientific Advisor | Board & advisors |
Cynthia Butitta | Independent Director | Board & advisors |
Carlo Rizzuto | Director | Board & advisors |
13 more people are available in the full profile.
Complete people profiles for Century Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Century Therapeutics
Century Therapeutics is a publicly listed company on the NASDAQ with ticker symbol IPSC in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date18 Jun 2021
- Listed onNASDAQ: IPSC
- Listed entityCentury Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS15673T1007
- Share price$1.38 (-4.17% on the day) · 2026-10-13
- Market capitalisation$249.9M
- EPS (diluted, trailing year)$-0.90
- Volume (last session)544,254
Financials of Century Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $109.2M | -$9.6M | -$1.9M |
| 2024 | $6.6M | -$126.6M | -$121.0M |
| 2023 | $2.2M | -$136.7M | -$112.1M |
| 2022 | $5.2M | -$130.9M | -$113.8M |
| 2021 | -$95.8M | -$90.3M |
Detailed financial statements for Century Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Century Therapeutics
Century Therapeutics has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Clade TX, Empirica Therapeutics and empirica.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Stem cell-derived therapies for cancer are developed using pluripotent cells. | cladetx.com | Cambridge, United States | 2020 | Apr 2024 | β’β’β’β’ | |
Research and consulting services are provided by empirica. | empirica.com | Bonn, Germany | 1988 | Jul 2020 | β’β’β’β’ | |
T-cell therapeutics are developed for brain cancer treatment. | empiricatx.com | Hamilton, Canada | 2018 | Jun 2020 | β’β’β’β’ |
Complete acquisition details for Century Therapeutics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Century Therapeutics
7 dated milestones of Century Therapeutics across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Century Therapeutics is founded.
- Funding First funding round of $250.0M.
- Acquisition Acquires Empirica Therapeutics.
- Acquisition Acquires empirica.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Clade TX.
- Funding Latest funding round, Post-IPO, of $135.0M.
Web traffic of Century Therapeutics
The website of Century Therapeutics (centurytx.com) receives about 9.7K visits a month and ranks #3,364,929 among all websites worldwide, #4,406 in Biotechnology and Pharmaceuticals.
- Monthly visits9.7K
▲ 78.1% vs previous month
- Unique visitors2.2K
per month
- Global rank#3,364,929
among all websites
- Category rank#4,406
Health · Biotechnology and Pharmaceuticals
- Bounce rate30%
- Pages per visit2.0
- Average visit50 sec
- DevicesDesktop 53% Β· Mobile 47%
Top companies in Oncology
3 companies that operate in the same segment as Century Therapeutics (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Century Therapeutics
Complete news archive for Century Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Century Therapeutics
Century Therapeutics was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Century Therapeutics is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Century Therapeutics is a funded company, having raised a total of $410M across 4 funding rounds to date. The company's 1st funding round was a Series C of $250M, raised on Jul 2019.
Century Therapeutics has 150 employees.
Annual revenue of Century Therapeutics is $109.16M as on Dec 31, 2025.
Century Therapeutics was founded in 2018 and is headquartered in Philadelphia, United States. Operations focus on the biotechnology sector, where adult stem cells are harnessed to create therapies targeting cancer. Novel allogeneic living drugs for oncology are being developed to address shortcomings in first-generation cell therapies. The companys efforts center on advancing these cellular treatments through research and development processes.
Century Therapeutics offers iPSC-derived NK Cell Therapies and iPSC-derived T Cell Therapies.
Yes, Century Therapeutics is publicly traded on NASDAQ under the ticker symbol IPSC.
Century Therapeutics has made 3 acquisitions, including Clade TX, Empirica Therapeutics, and empirica.
Century Therapeutics has 24 investors. Key investors include Fidelity Investments, Marshall Wace, FUJIFILM Cellular Dynamics, Orbimed, and RA Capital.
Century Therapeutics operates through Century Therapeutics, Inc..
